ATAI Alert: Law Firm Investigates Fairness of Eli Lilly Takeover at $6.75/Share + CVR

What happened

A law firm is investigating the fairness of the proposed sale of ATAI/AtaiBeckley to Eli Lilly for $6.75 per share in cash plus a contingent value right worth up to an additional $2.50. The offer represents a shift from the prior investment thesis centered on BPL-003 Phase 3 execution to a near-term deal valuation dependent on CVR milestones. The cash portion alone is slightly below the DeepValue base case of $5.80 and bull case of $6.80, but the CVR could push total consideration to $9.25 if fully realized. The investigation signals shareholder concern that the deal may not fully capture the pipeline's long-term potential, particularly given the absence of confirmed Phase 3 enrollment. The transaction supersedes the previous "WAIT"-and-monitor approach, as the outcome now hinges on deal terms, shareholder vote, and CVR achievements rather than clinical data readouts.

Implication

The proposed buyout shifts ATAI’s investment case from a long-duration clinical execution story to a deal arbitrage situation. At $6.75 cash, the offer is near the prior bull case of $6.80, but the CVR offers upside to $9.25, contingent on future milestones. However, the law firm investigation raises the possibility that the deal could be challenged or renegotiated, potentially leading to a higher price or termination. Investors should assess the probability of the CVR paying out, which depends on BPL-003 and other pipeline successes without the benefit of ATAI’s operational control. Until more clarity emerges on deal terms and shareholder sentiment, the stock may trade with a wider risk premium, making risk-reward uncertain.

Thesis delta

The DeepValue thesis that hinged on Phase 3 initiation and enrollment progress is now overtaken by a proposed acquisition. The primary driver shifts to whether the $6.75 + CVR offer appropriately values ATAI’s pipeline, especially given that the stock had a bull case of $6.80 based on clinical success. The law firm’s investigation suggests potential undervaluation, and the outcome may re-rate the stock toward the CVR-adjusted value or, if the deal fails, back to prior fundamentals.